Glioblastoma MultiformeEarly Phase 1NCT05432375
Study of Tinostamustine for Adjuvant Treatment of Glioblastoma
A Early Phase 1 study testing Tinostamustine in people with Glioblastoma Multiforme, run by Mundipharma Research Limited at 5 sites in 2 countries.
Trial summary
The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly diagnosed GBM who are MGMT unmethylated and have completed concomitant treatment with temozolomide and radiation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioblastoma Multiforme
- What is being tested?
- Tinostamustine
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 5 sitesin 2 countries
- Study dates
- 1 Jul 2022to 10 Nov 2024
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients must have Grade 4 isocitrate dehydrogenase (IDH) wild type GBM with local pathology confirmed MGMT-promoter unmethylated status.
- Patients must have undergone surgical resection of the GBM tumour and have completed standard radiation therapy with concurrent temozolomide and must not have clear signs of progression such as new disease outside the radiation area, neurological progression, or clinical progression that leads to other exclusion criteria.
- A baseline brain magnetic resonance imaging (MRI) obtained no more than 14 days prior to first dose of tinostamustine on a stable or decreasing dose of steroids for at least 5 days, is required prior to entrance of a patient onto the study.
- Patients must be registered on the study within 5 weeks of completion of concurrent chemoradiation.
- Patient must be willing and able to provide written informed consent for the study.
- Age ≥18 years on day of signing informed consent.
Show all 14Show fewer
- Prescribed treatment with concomitant temozolomide must be consistent with the EORTC-22981-26981 study (NCT00006353). The dose must be 75 mg/m2 daily for the 6 to 6.5 weeks of radiation therapy. The patient must have completed at least 75% of temozolomide dosing during radiotherapy.
- Confirmed IDH wild type. The presence of an IDH mutation will be exclusionary for study enrolment. IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e., IDH wild type). If a mutation is identified, then the patient will be ineligible.
- Patients must have a performance status of ≥60 on the Karnofsky Performance Scale (KPS).
- If patient is on steroids, patient must be on a stable or decreasing dose of steroids for at least 5 days at the time of baseline brain MRI.
- Demonstrate adequate organ function as defined in Table 3. All screening laboratories should be performed within 14 days (+/- 2 days) of treatment initiation.
- Serum potassium and magnesium at least at the lowest limit of normal (LLN) range, before every tinostamustine administration. If it is below LLN, supplementation is permissible.
- Female patients of childbearing potential should have a negative serum pregnancy test within 48 hours of starting first dose of tinostamustine.
- Female study participants of childbearing potential and their partners, and male study participants who intend to be sexually active with a woman of childbearing potential, must be willing to use at least TWO highly effective forms of contraception. This should start from the time of study enrolment and continue throughout tinostamustine administration. Female study participants of childbearing potential must continue using contraception for at least 6 months after the last administration of the tinostamustine. Female study participants should be willing to have a pregnancy test performed at screening, on Day -1 of each tinostamustine administration and at tinostamustine discontinuation. Male study participants who are sexually active with a woman of childbearing potential should also use a condom during treatment and for at least 90 days after the last administration of tinostamustine. Vasectomised males are considered fertile; therefore, vasectomised partners and patients must be willing to use a secondary method of effective birth control. Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the tinostamustine. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient.
Who cannot join
- Patient has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel® wafers will be excluded. Concomitant use of the tumour treating fields will also be excluded.
- Use of chemotherapy or immunotherapy within 21 days (apart from TMZ), use of targeted therapy within 14 days or 5 times the half-life of the agent, whichever is longer, prior to the first dose of tinostamustine. After the respective durations mentioned above, patients may be enrolled if they have recovered from any related toxicities ≥ Grade 1 (except alopecia). This applies to any prior systemic anticancer therapy including investigational agents.
- Any serious medical condition that interferes with adherence to study procedures.
- Patient has had prior chemotherapy (excluding radiotherapy + temozolomide), targeted small molecule therapy, within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 at baseline) from AEs due to a previously administered agent.
- Note: Patients with ≤Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Show all 25Show fewer
- Patients with a history of a second malignancy diagnosed within 3 years of study enrolment or have a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
- Implanted pacemaker or implantable cardiac defibrillator or New York Heart Association (NYHA) Stage III/IV congestive heart failure or with the following arrhythmias: atrial fibrillation/flutter with poor rate control; documented sustained ventricular tachycardia (defined as >30 seconds or requiring cardioversion before 30 seconds have elapsed) or TdP; ventricular pre excitation (Wolff Parkinson White syndrome) Brugada Syndrome; complete left bundle branch block (LBBB); QRS >120 ms; myocardial infarction or acute coronary syndrome within previous 6 months.
- Severe chronic obstructive pulmonary disease (COPD) or severe uncontrollable hypertension.
- Patients who did not complete at least 75% of temozolomide dosing during radiotherapy per EORTC-22981-26981 study.
- Patients who had a platelet count <75,000/mm3 during concomitant temozolomide therapy during radiation.
- Patients with QTc interval (Fridericia's formula) >450 ms.
- Patients who are on treatment with drugs known to prolong the QT/QTc interval. Selective serotonin reuptake inhibitors (SSRIs): Patients treated with a SSRI AND displaying a QTc prolongation are NOT eligible in the study.
- Nevertheless, there is no need to stop or change a SSRI if a patient is on a stable dose AND with no impact on QT/QTc interval, since it is not expected that plasma concentration of the SSRI will be affected by the administration of tinostamustine.
- Patient has known gliomatosis cerebri, leptomeningeal disease, extracranial disease, or multifocal disease. Patient has multifocal GBM, defined as discrete sites of contrast enhancing disease without contiguous T2/FLAIR abnormality that require distinct radiotherapy ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR abnormality as the main lesion(s) and that are encompassed within the same radiotherapy port as the main lesion(s) are permitted.
- Patient has an active infection requiring systemic therapy.
- Patient has an ongoing or previous history of spontaneous intratumoral haemorrhage.
- Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
- Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
- Patient is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit.
- Patient has a known history of human immunodeficiency virus (HIV type 1 or 2 antibodies). Testing not required.
- Patient has known active hepatitis B (e.g., HBs Ag reactive) or hepatitis C (e.g., HCV RNA [qualitative]) is detected.
- Patient has received a live vaccine within 30 days prior to the first dose of tinostamustine.
- Contraindication for undergoing MRIs.
- Use of any drug with histone deacetylase (HDAC) inhibiting activity including use of valproate in any of its indications (epilepsy, mood disorder). Valproate, due to its HDAC inhibiting activity is contraindicated. For those patients on valproate, valproate will need to be discontinued and switched to a different anti epileptic agent or psychotropic agent. A washout period of 4 days from valproate acid will be allowed prior to enrolling into the study.
Trial locations and contacts
5 sites in 2 countries.
5 sites in 2 countries
Spain3 sites
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Barcelona
Hospital Universitario Ramón y Cajal, Madrid, Spain
Madrid
South Texas Accelerated Research Therapeutics (START)
Madrid
About this study
Official title: A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients With Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma
The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly diagnosed GBM who are MGMT unmethylated and have completed concomitant treatment with temozolomide and radiation. Treatment with adjuvant tinostamustine will start within 5 weeks of completion of concomitant temozolomide and radiation. The study is designed to define the MTD by evaluating toxicities during dose escalation. Tinostamustine will be administered on Day 1 of a 21-day treatment cycle.
The total number of treatment cycles is 12 for patients who continue to benefit from treatment without disease progression or intolerable toxicity. Patients will enter a "3+3" design with dose escalation/de-escalation depending on safety from the last treated cohort.
- Conditions
- Glioblastoma Multiforme
- Being tested
- Tinostamustine
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TinostamustineDrug
infusion given over 60 minutes
| Study group | Role | What they receive |
|---|---|---|
| Tinostamustine | Experimental | Infusion delivered over 60 minutes Receives: Drug: Tinostamustine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose Limiting toxicity
Toxicity will be evaluated according to the most current version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity criteria
Measured: cycle 1 of treatment. Cycle 1 is 21 days duration with infusion given on day 1
Secondary outcomes (2)
Anti-tumour activity
Response assessment in neuro-oncology (RANO) criteria (to assess mPFS, PFS, ORR, OS, duration of response [DoR])
Measured: Approx 1 year from start of treatment
Pharmacokinetic assessment
plasma concentrations of tinostamustine
Measured: cycle 1 of treatment. Cycle is 21 days duration with infusion given on day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2022
- Study start1 Jul 2022
- Primary completion10 Nov 2024
- Study completion10 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glioblastoma MultiformeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mundipharma Research Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Tomas Janik, MD, Study director, Mundipharma Research Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05432375
- Sponsor's protocol ID
- EDO S101-1006
- Status last verified
- Dec 2025
- First submitted
- 9 Jun 2022
- Last updated
- 10 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Tinostamustine, a Novel Alkylating and Deacetylase Inhibiting Molecule, as Adjuvant Treatment in Patients With Newly Diagnosed Unmethylated MGMT-promoter Glioblastoma
- ClinicalTrials.gov ID
- NCT05432375
- Acronym / sponsor ID
- EDO S101-1006
- Conditions
- Glioblastoma Multiforme
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Mundipharma Research LimitedIndustry (pharma, biotech, devices)
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 10 Nov 2024 (actual)
- Study completion
- 10 Nov 2024 (actual)
- First posted
- 27 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly diagnosed GBM who are MGMT unmethylated and have completed concomitant treatment with temozolomide and radiation. Treatment with adjuvant tinostamustine will start within 5 weeks of completion of concomitant temozolomide and radiation. The study is designed to define the MTD by evaluating toxicities during dose escalation. Tinostamustine will be administered on Day 1 of a 21-day treatment cycle.
The total number of treatment cycles is 12 for patients who continue to benefit from treatment without disease progression or intolerable toxicity. Patients will enter a "3+3" design with dose escalation/de-escalation depending on safety from the last treated cohort.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Tinostamustine | Experimental | Drug: TinostamustineInfusion delivered over 60 minutes |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Patients must have Grade 4 isocitrate dehydrogenase (IDH) wild type GBM with local pathology confirmed MGMT-promoter unmethylated status.
- Patients must have undergone surgical resection of the GBM tumour and have completed standard radiation therapy with concurrent temozolomide and must not have clear signs of progression such as new disease outside the radiation area, neurological progression, or clinical progression that leads to other exclusion criteria.
- A baseline brain magnetic resonance imaging (MRI) obtained no more than 14 days prior to first dose of tinostamustine on a stable or decreasing dose of steroids for at least 5 days, is required prior to entrance of a patient onto the study.
- Patients must be registered on the study within 5 weeks of completion of concurrent chemoradiation.
- Patient must be willing and able to provide written informed consent for the study.
Key exclusion criteria (25 listed)
- Patient has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel® wafers will be excluded. Concomitant use of the tumour treating fields will also be excluded.
- Use of chemotherapy or immunotherapy within 21 days (apart from TMZ), use of targeted therapy within 14 days or 5 times the half-life of the agent, whichever is longer, prior to the first dose of tinostamustine. After the respective durations mentioned above, patients may be enrolled if they have recovered from any related toxicities ≥ Grade 1 (except alopecia). This applies to any prior systemic anticancer therapy including investigational agents.
- Any serious medical condition that interferes with adherence to study procedures.
- Patient has had prior chemotherapy (excluding radiotherapy + temozolomide), targeted small molecule therapy, within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 at baseline) from AEs due to a previously administered agent.
- Patients with a history of a second malignancy diagnosed within 3 years of study enrolment or have a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tinostamustineinfusion given over 60 minutes | Drug | Tinostamustine |
Primary outcome
Dose Limiting toxicity
Time frame: cycle 1 of treatment. Cycle 1 is 21 days duration with infusion given on day 1
Toxicity will be evaluated according to the most current version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity criteria
2 secondary outcomes
Anti-tumour activity
Time frame: Approx 1 year from start of treatment
Pharmacokinetic assessment
Time frame: cycle 1 of treatment. Cycle is 21 days duration with infusion given on day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Glioblastoma Multiforme
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tomas Janik, MD study director
Mundipharma Research Limited
5 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Tinostamustine in people with Glioblastoma Multiforme, run by Mundipharma Research Limited at 5 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Spain, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose Limiting toxicity (time frame: cycle 1 of treatment. Cycle 1 is 21 days duration with infusion given on day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2025.